Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
  MedlineGoogle Scholar
• 2. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3), 545–553 (2003).
  MedlineGoogle Scholar
• 3. Bonotto M, Gerratana L, Poletto E et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19(6), 608–615 (2014).
  MedlineGoogle Scholar
• 4. Bonotto M, Gerratana L, Di Maio M et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast 31, 114–120 (2017).
  MedlineGoogle Scholar
• 5. Chia SK, Speers CH, D'yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5), 973–979 (2007).
  MedlineGoogle Scholar
• 6. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl Cancer Inst. 99(6), 428–432 (2007). •• Panageas shows that the physician’s M-metastatic breast cancer (MBC) strategy could impact on the formal duration of PFS and therefore bias the consequent applicability of clinical trial-derived data.
  MedlineGoogle Scholar
• 7. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47(1), 207–214 (1981).
  Medline CASGoogle Scholar
• 9. Bonotto M, Gerratana L, Iacono D et al. Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? Oncologist 20(7), 719–724 (2015).
  MedlineGoogle Scholar
• 10. Accordino MK, Wright JD, Vasan S et al. Use and costs of disease monitoring in women with metastatic breast cancer. J. Clin. Oncol. 34(24), 2820–2826 (2016).
  MedlineGoogle Scholar
• 11. Bauml JM, Troxel A, Epperson CN et al. Scan-associated distress in lung cancer: quantifying the impact of “scanxiety.”. Lung Cancer 100, 110–113 (2016).
  MedlineGoogle Scholar
• 12. Bonotto M, Basile D, Gerratana L et al. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast 40, 45–52 (2018).
  MedlineGoogle Scholar
• 13. Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care 12(2), 101–106 (2017).
  Google Scholar
• 14. Cardoso F, Senkus E, Costa A et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)^†. Ann. Oncol. 29(8), 1634–1657 (2018). •• ESMO International Consensus Guidelines for Advanced BC recommends the strategy for imaging evaluation for endocrine therapy and for CHT, with a Level of Evidence and Grades of Recommendations and a consensus of 81%.
  Medline CASGoogle Scholar
• 15. Gradishar WJ, Anderson BO, Abraham J. NCCN Guidelines Index Table of Contents Discussion. Breast Cancer 3(18), 212 (2018).
  Google Scholar
• 16. Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of utilization of imaging studies and serum tumor markers among patients with de novo metastatic breast cancer. J. Natl Compr. Canc. Netw. 15(3), 316–324 (2017). • Di Meglio et al. describe the patterns of imaging and serum tumor marker use outside of clinical trials.
  MedlineGoogle Scholar
• 17. Accordino MK, Wright JD, Vasan S et al. Serum tumor marker use in patients with advanced solid tumors. J. Oncol. Pract. 12(1), 65–66 (2016). •• Accordino et al. define extreme users and not of disease-monitoring tests on the basis of monitoring patterns in clinical trials and of a previously published study about overuse of serum tumor marker testing.
  MedlineGoogle Scholar
• 18. Dinan MA, Curtis LH, Hammill BG et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 303(16), 1625–1631 (2010). • Dinan et al. show that disease monitoring impacts not only on clinical practice but also on health care costs, quality of life and on the interpretation and transferability of clinical studies' data.
  Medline CASGoogle Scholar
• 19. Ghezzi P, Magnanini S, Rinaldini M et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 271(20), 1587–1592 (1994).
  MedlineGoogle Scholar
• 20. Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol. Oncol. 100(3), 495–500 (2006).
  MedlineGoogle Scholar
• 21. Seah DSE, Luis IV, Macrae E et al. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J. Natl Compr. Canc. Netw. 12(1), 71–80 (2014).
  MedlineGoogle Scholar
• 22. Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 1925–1936 (2016).
  Medline CASGoogle Scholar
• 23. Smerage JB, Barlow WE, Hortobagyi GN et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 32(31), 3483–3489 (2014). •• Shows that an alternative M-MBC method may be represented by serial enumeration of circulating tumor cells during MBC treatment.
  Medline CASGoogle Scholar